thj-2201 (1-[(5-fluoropentyl)-1h-indazol-3-yl](naphthalen-1-yl)methanone) is a synthetic cannabinoid and analog of am-2201. it has been marketed by many research chemical vendors as a legal alternative to the popular am-2201, which had been banned in 2011.
cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. thj-2201 is orally active when dissolved in a lipid, which can increase the duration significantly. like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.
unlike cannabis, the chronic abuse of synthetic cannabinoids has been associated with multiple deaths and more dangerous side effects and toxicity in general. therefore, it is strongly discouraged to take this substance for extended periods of time or in excessive doses.
thj-2201, or 1-[(5-fluoropentyl)-1h-indazol-3-yl](naphthalen-1-yl)methanone, is a synthetic cannabinoid drug containing a substituted indazole group. this indazole moeity is substituted at r1 with a fluoropentyl chain, a substitution shared with 5f-pb-22 and 5f-akb48. additionally, the indazole core is substituted at r3 with a carbonyl group which is also bonded to a napthalene moeity. napthalene is a bicyclic structure of two fused benzene rings, and is also found in thj-018. the carbonyl bridge of thj-2201 classifies it as a ketone. thj-2201 is an analog of am-2201 in which the core indole structure is substituted with an indazole base.
although this substance has not been formally studied, from analysis of the structure, it is presumed that thj-2201 has a similar binding profile to that of am-2201 and matches many of the in vivo properties of δ9-thc. as with am-2201, this compound is believed to act as a potent full agonist to the central cb1 and peripheral cb2 receptors with ki values of 1.0 and 2.6nm respectively. however, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive.